FDA Grants Breakthrough Status to Heart Scaffold
The device could eventually offer patients with heart disease an alternative to permanent arterial implants.
Updated on Oct. 22, 2026 in Heart Disease
Live Poll
Do you trust that new medical device innovations generally lead to better long-term patient health outcomes?
The FDA has granted Breakthrough Device designation to the Freesolve resorbable scaffold, a device designed to provide temporary vessel support. Teleflex, the manufacturer, now plans to introduce this technology to patients in the United States.
Why it matters
This designation aims to accelerate the development and review process for the scaffold, which offers an alternative to permanent implants. By providing temporary support, the device seeks to reduce the long-term clinical risks associated with traditional, non-resorbable stents.
In clinical monitoring, the device demonstrated a 3.5% target lesion failure rate at four years. Furthermore, study observations indicate that 99% of the magnesium alloy is absorbed into the body one year after implantation.
The players
FDA
The federal agency responsible for protecting public health by regulating medical devices and overseeing the safety and efficacy of new technologies.
Teleflex
A medical device company that acquired the resorbable scaffold technology and plans to bring it to the United States market.
The details
The Freesolve scaffold is a catheter-delivered device built with a magnesium alloy and a bioabsorbable coating. It provides structural support to vessels during the healing process but is designed to be absorbed by the body over time, unlike traditional metallic stents that remain in the artery permanently. The FDA Breakthrough Device program is intended to expedite the development and review of technologies that offer more effective treatment for life-threatening conditions.
Timeline
Teleflex acquired the vascular business from Biotronik in 2025.
Teleflex ranked 55th among medical device companies by revenue in 2026.
Health Landscape
The development of bioabsorbable scaffolds represents a shift toward temporary vessel support, moving away from the standard of care involving permanent metallic implants. This approach aligns with broader medical trends seeking to minimize long-term foreign body responses in cardiovascular interventions.
This development is not yet available in the U.S. and currently has no impact on existing treatment plans or cardiac procedures. Patients interested in how new stent technology might eventually affect their care should consult with their cardiologist about current standard options.
The takeaway
The FDA is prioritizing the review of a new resorbable scaffold designed to support vessels without leaving behind a permanent implant. If you have concerns about your heart health, discuss the risks and benefits of various stent types with your physician.
Further reading
Learn more about the latest innovations in Heart Disease management.
Live Poll
Do you trust that new medical device innovations generally lead to better long-term patient health outcomes?
